Methods and compositions for inducing protective immunity against filovirus infection

Patent metadata

Field	Value
Publication number	US-11173201-B2
Application number	US-201916655516-A
Country	US
Kind code	B2
Filing date	Oct 17, 2019
Priority date	Sep 3, 2014
Publication date	Nov 16, 2021
Grant date	Nov 16, 2021

Abstract

The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

First claim

What is claimed is:

1. A method of inducing a protective immune response against a filovirus in a subject, the method comprising:
a. administering to the subject a first composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a first filovirus subtype, wherein the antigenic glycoprotein has the amino acid sequence of SEQ ID NO:1; and
b. administering to the subject a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding antigenic glycoproteins of at least two strains of filovirus subtypes;

wherein step (b) is conducted at least 8 weeks after step (a), and wherein the administration of (a) and (b) induces a protective immune response in the subject.

2. The method according to claim 1 wherein the first composition further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a second filovirus subtype.

3. The method according to claim 2 , wherein the first composition further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a third filovirus subtype.

4. The method according to claim 1 , wherein the first composition further comprises an adenovirus vector comprising a nucleic acid encoding the antigenic protein with SEQ ID NO:2.

5. The method according to claim 4 , wherein the first composition further comprises an adenovirus vector comprising a nucleic acid encoding the antigenic protein with SEQ ID NO:3.

6. The A method according to claim 1 , wherein the MVA vector in the second composition comprises a nucleic acid encoding antigenic proteins of at least four filovirus subtypes.

7. The method according to claim 1 , wherein the MVA vector in the second composition comprises a nucleic acid encoding antigenic proteins from four different filovirus subtypes having the amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 5.

8. The method according to claim 1 , wherein the adenovirus vectors are rAd26 or rAd35 vectors.

Assignees

• Bavarian Nordic As
• Janssen Vaccines & Prevention Bv
• Us Health

Inventors

• Volkmann Ariane
• Steigerwald Robin
• Dirmeier Ulrike
• Pau Maria Grazia
• Callendret Benoit Christophe Stephan
• Ward Lucy A

Classifications

• C12N2760/14234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/14171

  Demonstrated in vivo effect · CPC title

• C12N2760/14134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/572

  cytotoxic response · CPC title